Search
Approval of World's First Oral Targeted Therapy for HER2-Mutated Advanced Non-Small Cell Lung Cancer
4 day ago /
Read about 0 minute
Author：小编
On August 9, 2025, Boehringer Ingelheim's groundbreaking drug, Zolantinib Tablets, garnered approval from the U.S. Food and Drug Administration (FDA). This medication marks the first targeted oral therapy globally for advanced non-small cell lung cancer (NSCLC) with HER2-activating mutations, catering to adult patients with unresectable or metastatic non-squamous NSCLC who have undergone prior treatments. As a kinase inhibitor, Zolantinib Tablets introduces a novel treatment avenue for select lung cancer patients.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
